Annexin Pharmaceuticals AB operates as a biotechnology company. It develops treatment of various cardiovascular diseases. The firm establishes and optimizes a cell line for large-scale production of Annexin A5. The company was founded by Anna Frostegård in 2014 and is headquartered in Stockholm, Sweden.